StreetInsider.com News Articles

Form 8-K Biomea Fusion, Inc. For: Feb 25

Wed, 25 Feb 2026 06:06:00 -0500

si-local-file:///var/storage/secattach/20260225/26054742.html

Form 8-K Biomea Fusion, Inc. For: Feb 25

Wed, 25 Feb 2026 06:06:00 -0500

si-local-file:///var/storage/secattach/20260225/26054742.html

Biomea Fusion to Participate at Upcoming Investor Conferences

Thu, 19 Feb 2026 07:00:00 -0500

SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the following upcoming investor conferences:

Oppenheimer 36th Annual Healthcare Life Sciences Conference: Biomea will present virtually on February 26, 2026, at 10:00 AM (EDT). Company management will also meet with investors in one-on-one meetings during the conference.
The Citizens Life Sciences Conference: Biomea will present at 2:50 PM (EDT) on March 10, 2026, in Miami, FL. Company management will also

Biomea Fusion to Participate at Upcoming Investor Conferences

Thu, 19 Feb 2026 07:00:00 -0500

Oppenheimer 36th Annual Healthcare Life Sciences Conference: Biomea will present virtually on February 26, 2026, at 10:00 AM (EDT). Company management will also meet with investors in one-on-one meetings during the conference.
The Citizens Life Sciences Conference: Biomea will present at 2:50 PM (EDT) on March 10, 2026, in Miami, FL. Company management will also

Form SCHEDULE 13G/A Biomea Fusion, Inc. Filed by: CVI Investments, Inc.

Tue, 17 Feb 2026 14:46:00 -0500

si-local-file:///var/storage/secattach/20260217/26011301.html

Form SCHEDULE 13G/A Biomea Fusion, Inc. Filed by: CVI Investments, Inc.

Tue, 17 Feb 2026 14:46:00 -0500

si-local-file:///var/storage/secattach/20260217/26011301.html

Form SCHEDULE 13G Biomea Fusion, Inc. Filed by: Blue Owl Capital Holdings LP

Thu, 12 Feb 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260212/25991567.html

Form SCHEDULE 13G Biomea Fusion, Inc. Filed by: Blue Owl Capital Holdings LP

Thu, 12 Feb 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260212/25991567.html

Form SCHEDULE 13G/A Biomea Fusion, Inc. Filed by: Erdtmann Rainer M

Fri, 06 Feb 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260206/25962037.html

Form SCHEDULE 13G/A Biomea Fusion, Inc. Filed by: Erdtmann Rainer M

Fri, 06 Feb 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260206/25962037.html

Form 5 Biomea Fusion, Inc. For: Dec 31 Filed by: Erdtmann Rainer M

Fri, 06 Feb 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260206/25961740.html

Form 5 Biomea Fusion, Inc. For: Dec 31 Filed by: Erdtmann Rainer M

Fri, 06 Feb 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260206/25961740.html

Form 8-K Biomea Fusion, Inc. For: Jan 14

Wed, 14 Jan 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260114/25849921.html

Form 8-K Biomea Fusion, Inc. For: Jan 14

Wed, 14 Jan 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260114/25849921.html

Rodman & Renshaw Starts Biomea Fusion Inc. (BMEA) at Buy

Tue, 13 Jan 2026 07:19:41 -0500

(Updated - January 13, 2026 7:19 AM EST)

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Biomea Fusion Inc. (NASDAQ: BMEA) with a Buy rating and a price target of $8.00.

The analyst comments "We are initiating coverage of Biomea Fusion (NASDAQ: BMEA) with a BUY rating and an $8 price target, implying more than 500% upside from current levels. Biomea offers what many biotech investors eagerly seek: early clinical validation of a genuine disease-modifying mechanism combined with a valuation significantly disconnected from clinical progress where the stock appears to be priced for clinical failure rather than regulatory success."

For an

Rodman & Renshaw Starts Biomea Fusion Inc. (BMEA) at Buy

Tue, 13 Jan 2026 07:19:41 -0500

(Updated - January 13, 2026 7:19 AM EST)

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Biomea Fusion Inc. (NASDAQ: BMEA) with a Buy rating and a price target of $8.00.

For an

Biomea Fusion advances diabetes drug trials in 2026

Mon, 12 Jan 2026 08:00:37 -0500

Biomea Fusion Inc. (NASDAQ: BMEA) outlined its development priorities for 2026, focusing on advancing two investigational drugs for diabetes and obesity treatment. The clinical-stage biopharmaceutical company plans to initiate two Phase II trials for icovamenib and continue development of BMF-650.

The company completed a food-effect study for icovamenib in 60 participants during the fourth quarter of 2025, establishing that the drug achieves optimal exposure when administered within 30 minutes after a meal. Biomea also completed chronic toxicology studies for icovamenib in two species, with more than 400 subjects having received the drug to date.

Icovamenib is designed as a covalent menin inhibitor

Biomea Fusion advances diabetes drug trials in 2026

Mon, 12 Jan 2026 08:00:37 -0500

Icovamenib is designed as a covalent menin inhibitor

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Mon, 12 Jan 2026 08:00:00 -0500

Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like peptide-1 (“GLP-1”) based therapies
Successfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies
Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond the validated 12-week regimen
Advancing BMF-650 through clinical development as an oral next-generation GLP-1 receptor agonist candidate designed to deliver effective and patient-friendly metabolic benefits
Company to share 2026 strategy at the 44th Annual

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Mon, 12 Jan 2026 08:00:00 -0500

Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like peptide-1 (“GLP-1”) based therapies
Successfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies
Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond the validated 12-week regimen
Advancing BMF-650 through clinical development as an oral next-generation GLP-1 receptor agonist candidate designed to deliver effective and patient-friendly metabolic benefits
Company to share 2026 strategy at the 44th Annual

Form S-8 Biomea Fusion, Inc.

Tue, 06 Jan 2026 16:02:00 -0500
si-local-file:///var/storage/secattach/20260106/25813074.html

Form S-8 Biomea Fusion, Inc.

Tue, 06 Jan 2026 16:02:00 -0500
si-local-file:///var/storage/secattach/20260106/25813074.html

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Wed, 17 Dec 2025 07:00:00 -0500

SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from January 12-15.

A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Wed, 17 Dec 2025 07:00:00 -0500

SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from January 12-15.

A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media

Form 4 Biomea Fusion, Inc. For: Dec 11 Filed by: Erdtmann Rainer M

Mon, 15 Dec 2025 16:15:00 -0500
si-local-file:///var/storage/secattach/20251215/25740871.html